Recruiting
Phase 3

Dapsone Coronavirus SARS-CoV-2 Trial (DAP-CORONA) COVID-19

Sponsor:

McGill University Health Centre/Research Institute of the McGill University Health Centre

Code:

NCT04935476

Conditions

COVID-19

Eligibility Criteria

Sex: All

Age: 40+

Healthy Volunteers: Not accepted

Interventions

Dapsone 85 mg PO BID

Placebo 85 mg PO BID

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-28. This information was provided to ClinicalTrials.gov by McGill University Health Centre/Research Institute of the McGill University Health Centre on 2022-02-24.